Data Insights
PsiOxus completes patient enrolment in cancer cachexia drug Phase II study
UK-based development stage biotechnology company PsiOxus Therapeutics has finished enrolling patients in a double-blind, multinational, placebo-controlled, randomised Phase II clinical study of its small molecule therapeutic for the treatment of cancer cachexia, a wasting syndrome characterised by loss of muscle and fat.
Regeneron, Bayer commence Phase III trial of Eylea injection
Regeneron Pharmaceuticals and Bayer HealthCare have commenced a new Phase III trial of their Eylea (aflibercept) injection for the treatment of diabetic macular edema (DME) in Russia, China, and other Asian countries.
Psyadon enrols first patients in ecopipam Phase III study
Psyadon Pharmaceuticals has enrolled the first patients in a multicentre, double-blind, randomised three-way crossover Phase III study of ecopipam for the treatment of self-injurious behaviors in patients with Lesch-Nyhan disease, a rare inherited disorder.
Adynxx enrols first patient in investigational AYX1 Phase II study
Clinical-stage pharmaceutical company Adynxx has enrolled the first patient in a placebo-controlled Phase II clinical study of its lead investigational drug candidate, AYX1.
EGEN commences ovarian cancer drug Phase I trial
EGEN, a clinical stage biopharmaceutical company, has commenced a Phase I trial of EGEN-001, an immunotherapy agent for the treatment of advanced ovarian cancer.
Lithera commences fat reduction drug LIPO-202 Phase IIb trial
Lithera, a US-based clinical stage pharmaceutical company, has commenced a Phase IIb trial of LIPO-202, an injectable pharmaceutical product designed to target aesthetic reduction of subcutaneous abdominal fat.
UK court sentences pre-clinical trial data scam case accused to three months in prison
Edinburgh Sheriff's Court in the UK has sentenced a former employee of drug discovery and development firm Aptuit to three months in prison for altering pre-clinical trial data designed to support applications to perform clinical trials.
Protalex reports positive interim review of phase 1b rheumatoid arthritis trial
Clinical-stage biopharmaceutical company Protalex has reported positive interim review of phase 1b trial of PRTX-100 in rheumatoid arthritis (RA) by an independent data safety monitoring committee.
Mirna initiates Phase I trial of anti-cancer drug MRX34
MicroRNA therapy developer Mirna Therapeutics has commenced a Phase I trial of anti-cancer drug MRX34.
Takeda begins TOURMALINE-MM2 phase 3 trial of multiple myeloma drug
Takeda Pharmaceutical Company has began its TOURMALINE-MM2 phase 3 trial of MLN9708 in patients with newly diagnosed multiple myeloma.
CSL Behring doses first patient in Phase I/III pivotal study of haemophilia A candidate
Biopharmaceutical company CSL Behring has dosed the first patient in part 3 of its Affinity clinical trial programme, a Phase I/III pivotal study evaluating recombinant single-chain factor VIII (rVIII-SingleChain) for the treatment of haemophilia A.
Moberg completes patient enrolment in MOB-015 Phase II trial
Moberg Pharma, a Swedish pharmaceutical company, has announced the completion of patient enrolment in the ongoing Phase II trial of MOB-015.
RedHill Biopharma begins patient screening for Phase IIa multiple sclerosis trial
Israeli biopharmaceutical company RedHill Biopharma has started screening patients for a Phase IIa trial designed to evaluate the efficacy and safety of RHB-104 in multiple sclerosis.
Tumour-targeting ADCs: delivering the anti-cancer warhead
Antibody-drug conjugates combine the efficacy of cytotoxic drugs and the tumour-specific targeting of antibodies to maximise anti-cancer potency and minimise side effects. Chris Lo talks to experts in the field of ADC development to discover the potential of this burgeoning treatment type, and the challenges involved in getting it right.
Breaking barriers – the potential of subcutaneous drug delivery
Cancer rates are rising sharply just as healthcare providers are being asked to implement enormous efficiency savings, making innovation crucial to the future of cancer care. Elly Earls met Halozyme's Kurt Gustafson and Roche Products' Julian Cole, to find out how a revolutionary new subcutaneous drug delivery platform called ENHANZE™ could be part of the solution.
Trevena, Forest Laboratories partner to develop cardiovascular drug
Trevena and Forest Laboratories have collaborated to develop TRV027, an AT1R biased-ligand for the treatment of acute heart failure.
FDA approves Galderma's paediatric acne treatment
The US Food and Drug Administration (FDA) has approved Galderma Laboratories' Epiduo (adapalene 0.1% / BPO 2.5%) gel for the treatment of acne in children as young as nine.
June's top stories: China-Germany quality alliance, AstraZeneca cancer focus
The CCCMHPIE and German Good Manufacturing Practices third party auditor form alliance for drug quality, while Genmab and ADC Therapeutics collaborate to develop new antibody-drug conjugate (ADC) product for multiple cancer indications. Drugdevelopment-technology.com wraps up key headlines from June 2013.
CytomX partners with Pfizer to develop Probody drug conjugates in oncology
Biotechnology company CytomX Therapeutics has signed a strategic agreement with Pfizer for the development and commercialisation of multiple Probody drug conjugates (PDCs) in the field of oncology.
TheraVida, SK Chemicals sign licensing deal for overactive bladder medicines
TheraVida and SK Chemicals have signed a licensing deal for the development and commercialisation of THVD-201 and THVD-202, for overactive bladder (OAB) and urge urinary incontinence (UUI), in South Korea.